Compliance characteristics of long-acting injection therapy for community-dwelling schizophrenia patients under policy support
Zhang Yayun
Wu Hemin
Zhang Weibo
Lu Yi
Abstract：Objective To explore the characteristics of compliance with long-acting injections of paliperidone palmitate in community-dwelling schizophrenia patients under policy support.Methods The study population comprised schizophrenia patients who received paliperidone palmitate injections at designated hospitals under the long-acting medication policy in Baoshan District,Shanghai from August 2020 to December 2022.Through a one-year real-world follow-up,patients'general demographic information,clinical data,and treatment status with paliperidone palmitate were collected.Univariate analysis and multivariate Logistic regression analysis were employed to investigate factors influencing compliance with long-acting injections of paliperidone palmitate among community-dwelling schizophrenia patients.Results A total of 259 patients with schizophrenia were included in the study,with 5 lost to follow-up.Among patients receiving standardized treatment with paliperidone palmitate long-acting injection,161(63.39%)maintained continuous treatment for one year(compliance group),while 93(36.61%)discontinued treatment(discontinuation group).Statistically significant differences were observed between compliance group and discontinuation group in terms of home supervision,self-awareness,social functioning,and number of oral medications(all P＜0.05).Multivariate Logistic regression analysis indicated that weak home supervision[OR=2.06,95%CI(1.03,4.15)],lack of self-awareness[OR=2.53,95%CI(1.03,6.23)],and number of oral medications≥4[OR=3.85,95%CI(1.33,11.16)]were risk factors for poor treatment compliance with paliperidone palmitate(all P＜0.05).Conclusions Home supervision,self-awareness,and number of oral medications are factors associated with treatment compliance with paliperidone palmitate among community-dwelling schizophrenia patients.
Keywords：SchizophreniaPaliperidone palmitate long-acting injectionCompliancePolicyCharacteristics
Publication Date：2025-11-20
Online Publishing Date：2025-11-28(First online date of this platform, not the publication date of the document)
Pages：7( 816-822 )